Johnson & Johnson
- NYSE
- JNJ
- CIK
- 200406
- Industry
- Pharmaceutical Preparations
- Based in
- New Brunswick, New Jersey
- Incorporated in
- New Jersey
- Fiscal year ends
- January 3
- SEC filer category
- Large accelerated filer
- Employer ID (EIN)
- 22-1024240
- Formerly
- Johnson & Johnson ET AL
About
AI summary. This paragraph was summarized by AI from the company’s annual report. It may contain mistakes: check it against the source. How it was written
Johnson & Johnson is a holding company whose operating subsidiaries research, develop, manufacture and sell products in the healthcare field, with a primary focus on human health and well-being. Incorporated in New Jersey in 1887, it conducts business in virtually all countries of the world. The Company is organized into two segments. Innovative Medicine provides prescription medicines in oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism, including DARZALEX, STELARA, TREMFYA and XARELTO, distributed to retailers, wholesalers, distributors, hospitals and healthcare professionals. MedTech develops and manufactures cardiovascular, orthopaedics, surgery and vision products, such as electrophysiology devices, Abiomed heart pumps, Shockwave products, surgical instruments and ACUVUE contact lenses, used by physicians, hospitals, eye care professionals and clinics.
Source: the Business section of the company’s 10-K filed Feb 11, 2026.
Key figures
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Jan 2023 | Jan 2022 |
|---|---|---|---|---|---|
| Revenue | $94.2B | $88.8B | $85.2B | $80.0B | $78.7B |
| Net income | $26.8B | $14.1B | $35.2B | $17.9B | $20.9B |
| Diluted EPS | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 |
| Cash from operations | $24.5B | $24.3B | $22.8B | $21.2B | $23.4B |
| Total assets | $199.2B | $180.1B | $167.6B | $187.4B | $182.0B |
| Shareholders’ equity | $81.5B | $71.5B | $68.8B | $76.8B | $74.0B |
From the company’s annual reports to the SEC. Each year links to its report.
Financials 141
- 10-Q Quarterly Report for period ending Sep 27, 2026
- 10-Q Quarterly Report for period ending Jun 28, 2026
- 10-Q Quarterly Report for period ending Mar 29, 2026
- 10-K Annual Report for period ending Dec 28, 2025
- 10-Q Quarterly Report for period ending Sep 28, 2025
- 10-Q Quarterly Report for period ending Jun 29, 2025
- 10-Q Quarterly Report for period ending Mar 30, 2025
- 10-K Annual Report for period ending Dec 29, 2024
- 10-Q Quarterly Report for period ending Sep 29, 2024
- 10-Q Quarterly Report for period ending Jun 30, 2024
News 325
Ownership 2,167
- 4 Forminard Elizabeth (EVP, Chief Legal Officer): sold 13,072 shares at $284.39 ($3.7M), acquired 13,072 shares from options or stock units
- 144 Forminard Elizabeth (Officer): plans to sell 13,072 shares ($3.7M)
- 4 Pinto Daniel E (Director): was granted 113 stock units
- 4 Woods Eugene A.: Change in insider ownership
- 4 Hewson Marillyn a: Change in insider ownership
- 4 Schmid Timothy: Change in insider ownership
- 144 Schmid Timothy: Notice of proposed sale of restricted stock
- 3 Cavanaugh Thomas: Initial statement of insider ownership
- 4 Taubert Jennifer L: Change in insider ownership
- 144 Taubert Jennifer L: Notice of proposed sale of restricted stock
Prospectus 343
- S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
- 424B2 Prospectus filed pursuant to Rule 424(b)(2)
- 424B2 Prospectus filed pursuant to Rule 424(b)(2)
- FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
- 424B5 Prospectus filed pursuant to Rule 424(b)(5)
- FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
- 424B5 Prospectus filed pursuant to Rule 424(b)(5)
- 424B2 Prospectus filed pursuant to Rule 424(b)(2)
- 424B2 Prospectus filed pursuant to Rule 424(b)(2)
- FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
Proxies 95
- DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
- DEF 14A Definitive proxy statements
- DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
- DEF 14A Definitive proxy statements
- DFAN14A Intra-Cellular Therapies, Inc.: Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material
- DFAN14A Intra-Cellular Therapies, Inc.: Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material
- DFAN14A Intra-Cellular Therapies, Inc.: Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material
- DFAN14A Intra-Cellular Therapies, Inc.: Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material
- DFAN14A Shockwave Medical, Inc.: Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material
- DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
Other 305
- 13F-HR 15 holdings worth $761.7M
- N-PX Annual Report of Proxy Voting Record of Registered Management Investment Companies filed on Form N-PX
- 13F-HR 15 holdings worth $798.7M
- 11-K Annual report of employee stock purchase, savings and similar plans
- 11-K Annual report of employee stock purchase, savings and similar plans
- SD Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
- 13F-HR Institutional holdings report
- 13F-HR/A 17 holdings worth $555M
- 13F-HR/A Institutional holdings report
- ARS Annual report to security holders